Pediatric Hematology/Oncology

ASH 2025

Questions discussed in this category

What are your top takeaways in Hematologic Malignancies from ASH 2025?

What are your top takeaways in Lymphoma from ASH 2025?

What are your top takeaways in Classical Hematology from ASH 2025?

How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?

Aza/ven patients had better EFS/QoL with a greater proportion of patients who successfully got to a stem cell transplant. Provided that the OS data is...

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2025 Dec 09

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

Blood, 2025 May 15

How I treat challenging transfusion cases in sickle cell disease.

Lancet (London, England), 2025 Dec 07

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Lancet (London, England), 2025 Dec 05

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

The New England journal of medicine, 2025 Dec 06

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Blood, 2024 Feb 08

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).

Pediatric Hematology/Oncology

ASH 2025

Questions discussed in this category

Papers discussed in this category

Related Topics in Pediatric Hematology/Oncology